Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In.
Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year ago.
Related Articles
Alzheimer’s Drug Leqembi Sees Sales Pickup, Boosting Biogen Stock
Sales of a groundbreaking new Alzheimer’s disease treatment from Eisai and Biogen are finally accelerating, after a sluggish launch last year. Biogen said Wednesday that…
Person Tests Positive for Bird Flu in Texas After Exposure to Cattle
It is the second known case of H5N1 infection in the U.S.
Exclusive | First Medicare Health Plans to Start Paying for Weight-Loss Drug Wegovy
The first major U.S. health insurers have agreed to start paying for the popular anti-obesity drug Wegovy for certain people on Medicare with heart-related conditions.
Exclusive | Johnson & Johnson Considers Deal for Shockwave Medical
The California-based maker of medical devices that treat cardiovascular diseases has a market value of nearly $12 billion.
WSJ News Exclusive | This Doctor Found His Own Miracle Drug. Now He Wants to Do It for Others.
A new database aims to match rare-disease patients with drugs on pharmacy shelves.
The Cancer That Doctors Don’t Want to Call Cancer
Renaming the lowest-risk prostate cancer would cut down on overly aggressive treatment, some doctors say.
The Cancer That Doctors Don’t Want to Call Cancer
Renaming the lowest-risk prostate cancer would cut down on overly aggressive treatment, some doctors say.
The Downside of a Longer Life: More Time Spent Sick
Medical advances are turning fatal illnesses into chronic ones, and some health problems are hitting us earlier and more widely.
The Downside of a Longer Life: More Time Spent Sick
Medical advances are turning fatal illnesses into chronic ones, and some health problems are hitting us earlier and more widely.
The Downside of a Longer Life: More Time Spent Sick
Medical advances are turning fatal illnesses into chronic ones, and some health problems are hitting us earlier and more widely.